Yikon Genomics (Suzhou) Co. Ltd.

Company Overview

Yikon Genomics Co. Ltd., founded in 2012, is developing and commercializing a single-cell, whole-genome amplification technology licensed from Harvard University.

High-quality amplification is particularly important for clinical applications, because there is a low tolerance for false positives or negatives.

Yikon markets products in three application areas: reproductive health, cancer diagnostics and life science research.

Products for reproductive health include PGS, PGD and NIPT. These products use the MALBAC single cell sequencing technology platform.

Products for cancer diagnostics include genetic tests for personalized cancer therapy, HER2 amplification and BRCA 1/2 mutations. These diagnostics are liquid biopsy format and use the MALBAC-NGS technology platform.

Company's Business Segments

• Genetic Testing : Reproductive Genetic Testing, Cancer Genetic Testing, Single Cell WGS, MALBAC single cell whole genome amplification technology.
• Single Cell whole Genome and Transcriptome Sequencing Technologies : Under this segment, the company provides reproductive health, integrated lab solutions, reagent kits, instruments, and consumables. It also offers medical diagnostic services, reagents, and software for reproductive genetics and cancer personalized medicines.